Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Holding MTNB?
Track your performance easily
MTNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $21.50
Previous Close$0.54
Volume120.24K
Average Volume (3M)219.49K
Market Cap
$2.87M
Enterprise Value-$4.85M
Total Cash (Recent Filing)$10.79M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Mar 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding5,086,985
10 Day Avg. Volume691,043
30 Day Avg. Volume219,486
Standard Deviation0.28
R-Squared0.10
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.17
Price to Sales (P/S)2.62
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.43
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
Matinas BioPharma News
PremiumCompany Announcements
Matinas BioPharma Faces Uncertain Future After Halting MAT2203 Development
PremiumPre-Earnings
Is MTNB a Buy, Before Earnings?PremiumCompany Announcements
Matinas BioPharma Slashes Workforce Amid Financial Turmoil
Bulls Say, Bears Say
Bulls Say
Clinical Study LaunchOnce a partner is secured, the company will shift focus towards launching its P3 ORALTO study of MAT2203 in IA patients.
Innovative Drug DeliveryMAT2203 is an application of Matinas's lipid nanocrystal (LNC) delivery that makes amphotericin available by oral administration and has demonstrated safety at high doses for sustained periods of time.
Partnership AgreementMatinas announced it entered a non-binding agreement with an undisclosed partner for global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections.
Bears Say
Financial HealthThe company lacks funds to materially advance any programs forward.
Leadership ChangesMatinas is implementing 80% workforce reduction, eliminating 15 positions, including departure of the CMO, CBO and CTO.
Strategic PartnershipPartnering negotiations for its lead asset MAT2203 were terminated by the prospective partner.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MTNB FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was $0.50 and its highest was $21.50 in the past 12 months.
What is Matinas BioPharma’s market cap?
Currently, no data Available
When is Matinas BioPharma’s upcoming earnings report date?
Matinas BioPharma’s upcoming earnings report date is Mar 18, 2025 which is in 115 days.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on Nov 06, 2024. The company reported -$0.849 earnings per share for the quarter, beating the consensus estimate of -$0.925 by $0.076.
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 5,086,985 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -$0.849 in its last earnings report, beating expectations of -$0.925. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Among the largest hedge funds holding Matinas BioPharma’s share is Highbridge Capital Management LLC. It holds Matinas BioPharma’s shares valued at 457K.
---
Matinas BioPharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 83.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.38%
12-Months-Change
Fundamentals
Return on Equity
-108.57%
Trailing 12-Months
Asset Growth
-30.93%
Trailing 12-Months
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
---
MTNB Earnings Call
Q2 2024
0:00 / 0:00
---
MTNB Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---